Thursday, 15 October 2026European Markets

CNOVA Stock Is 26% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of cnova (cac 40: cnv.pa) jumped by a staggering 26.27% in 10 sessions from €2.55 to €3.22 at 14:54 est on thursday, after five successive sessions in a row of losses. cac 40 is rising 0.36% to €7,353.35, after two consecutive sessions in a row of gains.

cnova's last close was €3.00, 42.31% under its 52-week high of €5.20.

about cnova

cnova n.v. operates as an e-commerce company in france and western europe. the company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. it also operates cdiscount voyages, a travel platform; cdiscount mobile for cell phone plans; cdiscount advertising, a digital marketing solution; octopia for turnkey marketplace solutions to retailers and e-merchants; and c-logistics for transportation and logistics services. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. cnova n.v. is a subsidiary of casino, guichard-perrachon s.a.

earnings per share

as for profitability, cnova has a trailing twelve months eps of €-0.35.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cnova's stock is considered to be overbought (>=80).

volume

today's last reported volume for cnova is 630 which is 68.46% below its average volume of 1998.

revenue growth

year-on-year quarterly revenue growth declined by 29%, now sitting on 1.7b for the twelve trailing months.

moving average

cnova's worth is way below its 50-day moving average of €3.65 and under its 200-day moving average of €3.43.

more news about cnova (cnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com